Triamcinolone hexacetonide ( DrugBank: Triamcinolone )

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	2
107	Juvenile idiopathic arthritis	2

46. Malignant rheumatoid arthritis

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-000993-20-SE (EUCTR)	04/12/2014	02/09/2014	Dosing of glucocorticoid (triamcinolone hexacetonid) when injecting knee joints of rheumatic diseases	Dosing of intraarticular triamcinolone hexacetonid for knee synovitis in chronic polyarthritis	Psoriatic arthritis and rheumatoid arthritis with synovitis of the knee;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512	Center for Research and Development Uppsala University/County Council of Gävleborg	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 4	Sweden
2	NCT01851278 (ClinicalTrials.gov)	April 2013	12/4/2013	Effectiveness Intraarticular Corticosteroid	Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose	Rheumatoid Arthritis	Drug: Triamcinolone hexacetonide	Federal University of São Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Recruiting	18 Years	65 Years	Both	60	N/A	Brazil

107. Juvenile idiopathic arthritis

Clinical trials : 441 / Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04614311 (ClinicalTrials.gov)	December 1, 2020	28/10/2020	Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).	Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA): The MyJIA Trial.	Juvenile Idiopathic Arthritis	Drug: Triamcinolone Hexacetonide 20 MG/ML	Oslo University Hospital	The Research Council of Norway;Haukeland University Hospital;St. Olavs Hospital;University Hospital of North Norway;Helse Stavanger HF	Recruiting	1 Year	18 Years	All	202	Phase 4	Norway
2	EUCTR2019-000889-38-NO (EUCTR)	16/09/2020	18/06/2020	Personalised treatment of my juvenile arthritis	Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intra-articular glucocorticoid injections in JIA patients starting tumour necrosis factor inhibitor treatment - MyJIA	Juvenile idiopathic arthritis is characterised by inflamed joints and is the most common chronic rheumatic disease in childhood and adolescence that potentially lead to disability due to joint damage. A prerequisite for the JIA diagnosis is the detection of inflammation of one or more joints (arthritis). Arthritis leads to pain, swelling and stiffness of the affected joints, caused by hypertrophy of the synovial lining of the joint and increased synovial fluid. Untreated, disability may follow.;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Lederspan INN or Proposed INN: TRIAMCINOLONE HEXACETONIDE	Oslo University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	202	Phase 4	Norway